SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Document › Details

Pieris Pharmaceuticals, Inc.. (3/22/16). "Press Release: Pieris Pharmaceuticals Reports Full-Year 2015 Financial Results and Corporate Update". Boston, MA.

Organisations Organisation Pieris Pharmaceuticals Inc. (Nasdaq: PIRS)
  Group Pieris (Group)
  Organisation 2 Sanofi (Group) [since May 2011]
Products Product PRS-343 (CD137/HEr2 bispecfic anticalin-based drug, Pieris)
  Product 2 PRS-080 (Anticalin hepcidin antagonist)
Index terms Index term Roche–Pieris: cancer immunotherapy, 201512– collab + license ww up to CHF415m + royalties r+d of Anticalin-based drugs against Roche target
  Index term 2 Daiichi Sankyo–Pieris: Anticalin scaffold technology, 201104– collab €7m upfront + up to €200m + royalties drug discovery Anticalins for 2 targets
Persons Person Deptula-Hicks, Darlene (Pieris 201509–201702 CFO before consultant to Pieris RESIGNED 2/17)
  Person 2 Yoder, Stephen S. (Steve) (Pieris 201001– CEO before MorphoSys Head Licensing + IP)

Record changed: 2019-04-26


Picture [LSUS] – The Business Web Portal 600x60px

More documents for Pieris (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSG] – The Business Web Portal 600x80px

» top